MX2012011666A - Cluap1 peptides and vaccines including the same. - Google Patents

Cluap1 peptides and vaccines including the same.

Info

Publication number
MX2012011666A
MX2012011666A MX2012011666A MX2012011666A MX2012011666A MX 2012011666 A MX2012011666 A MX 2012011666A MX 2012011666 A MX2012011666 A MX 2012011666A MX 2012011666 A MX2012011666 A MX 2012011666A MX 2012011666 A MX2012011666 A MX 2012011666A
Authority
MX
Mexico
Prior art keywords
peptides
cluap1
methods
antigen
inducing
Prior art date
Application number
MX2012011666A
Other languages
Spanish (es)
Inventor
Yusuke Nakamura
Ryuji Ohsawa
Takuya Tsunoda
Sachiko Yoshimura
Tomohisa Watanabe
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of MX2012011666A publication Critical patent/MX2012011666A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides

Abstract

Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the CLUAP1 gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing as active ingredient peptides derived from CLUAP1 or polynucleotides encoding the peptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis (i.e., prevention) of cancers (tumors), and/or the prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from CLUAP1, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.
MX2012011666A 2010-04-08 2010-10-26 Cluap1 peptides and vaccines including the same. MX2012011666A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32209910P 2010-04-08 2010-04-08
PCT/JP2010/006313 WO2011125139A1 (en) 2010-04-08 2010-10-26 Cluap1 peptides and vaccines including the same

Publications (1)

Publication Number Publication Date
MX2012011666A true MX2012011666A (en) 2012-12-17

Family

ID=44762128

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012011666A MX2012011666A (en) 2010-04-08 2010-10-26 Cluap1 peptides and vaccines including the same.

Country Status (9)

Country Link
JP (1) JP2013523083A (en)
KR (1) KR20130043632A (en)
AU (1) AU2010350389A1 (en)
BR (1) BR112012025486A2 (en)
CA (1) CA2795423A1 (en)
MX (1) MX2012011666A (en)
SG (1) SG184468A1 (en)
TW (1) TW201134480A (en)
WO (1) WO2011125139A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3971769B2 (en) * 2002-09-12 2007-09-05 オンコセラピー・サイエンス株式会社 KDR peptide and vaccine containing the same
TW201000115A (en) * 2008-06-11 2010-01-01 Oncotherapy Science Inc IQGAP3 epitope peptides and vaccines containing the same

Also Published As

Publication number Publication date
TW201134480A (en) 2011-10-16
CA2795423A1 (en) 2011-10-13
JP2013523083A (en) 2013-06-17
KR20130043632A (en) 2013-04-30
AU2010350389A1 (en) 2012-10-25
WO2011125139A1 (en) 2011-10-13
SG184468A1 (en) 2012-11-29
BR112012025486A2 (en) 2017-01-10

Similar Documents

Publication Publication Date Title
MX2010014044A (en) Cdca1 epitope peptides and vaccines containing the same.
PH12015502638A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MX2015012012A (en) Kntc2 peptides and vaccines containing the same.
GB201004575D0 (en) Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
EP3708185A3 (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)
PH12021551208A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MX2016014711A (en) Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml).
MX362912B (en) Ube2t peptides and vaccines containing the same.
MX2011012013A (en) Ttk peptides and vaccines including the same.
MX355759B (en) Topk peptides and vaccines including the same.
MX2011010191A (en) C6orf167 peptides and vaccines containing the same.
MX2022006022A (en) Depdc1-derived peptide and vaccine containing same.
SG10201900933YA (en) Koc1-derived peptide and vaccine including same
EP4219525A3 (en) Foxm1-derived peptide, and vaccine including same
MX2015007015A (en) Sema5b peptides and vaccines containing the same.
EP4282883A3 (en) Cdca1-derived peptide and vaccine containing same
MX2012011666A (en) Cluap1 peptides and vaccines including the same.
MX2021001357A (en) Cdca1-derived peptide and vaccine containing same.
SG10201900835XA (en) Urlc10-derived peptide and vaccine containing same
BR112013005448A2 (en) tt114 peptides and vaccines containing them.
MX2012006376A (en) Mybl2 peptides and vaccines containing the same.
MX2019013163A (en) Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml).
MY194241A (en) Novel Immunotherapy Against Several Tumors, Such as Lung Cancer, Including NSCLC
MY193910A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
MY194653A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc

Legal Events

Date Code Title Description
FA Abandonment or withdrawal